Seeking Alpha

BioCryst Pharmaceuticals, Inc. (BCRX)

  • Mon, Jan. 26, 7:49 AM
    • The FDA grants Fast Track status to BioCryst Pharmaceuticals' (NASDAQ:BCRX) plasma kallikrein inhibitor BCX4161 for the treatment of hereditary angioedema. The product candidate is currently in Phase 2/3 development. Clinical trial results are expected by the end of this year.
    • Fast Track designation allows for more frequent interactions with the FDA review team and a rolling review of the New Drug Application (NDA).
  • Thu, Jan. 22, 12:12 PM
    • Thinly-traded micro cap NanoViricides (NNVC +20.5%) moves up in early trading on higher volume albeit on modest turnover of 230K shares. Before the open, the company announced that it shipped several anti-Ebola nanoviricide drug candidates to an unnamed "hi-security bio-containment facility" for evaluation.
    • The company states that it progressed from design to synthesis of the drug candidates in only four months using its rapid design platform.
    • Related tickers: (TKMR +0.2%)(BCRX -2.9%)(HEB -3.2%)(INO -2.3%)(SRPT -0.4%)(CMRX -1.4%)(ABIO -1.6%)
    | Comment!
  • Wed, Jan. 14, 7:31 AM
    • Europe's Committee for Orphan Medicinal Products (COMP) issues a positive opinion on BioCryst Pharmaceuticals' (NASDAQ:BCRX) application for Orphan Drug designation for BCX4161 for the treatment of patients with hereditary angioedema (HAE). The European Commission will make the final decision on the application.
    • BCX4161 is a plasma kallikrein inhibitor which, in turn, suppresses bradykinin production. Bradykinin is the mediator of acute swelling attacks in patients with HAE.
    • The FDA designated BCX4161 an Orphan Drug several weeks ago.
    • Previously: BioCryst plasma kallikrein an Orphan Drug for HAE (Dec. 24, 2014)
  • Mon, Jan. 5, 7:19 AM
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) appoints Ms. Lynne Powell as SVP and Chief Commercial Officer effective January 26. She joins the firm from CSL Behring where she was SVP of North American Commercial Operations.
    | Comment!
  • Dec. 30, 2014, 1:53 AM
    • A health-care worker infected with Ebola was admitted to a specialist unit in a Glasgow hospital yesterday after she returned from working with Ebola patients in Sierra Leone.
    • She is the second Ebola patient to be treated in the country since the outbreak of the disease and will be transferred to the U.K.’s specialized high-isolation unit at the Royal Free Hospital in London as soon as possible.
    • Ebola-related stocks are rising after-hours on the news: Tekmira (NASDAQ:TKMR) +1.7%; BioCryst Pharmaceuticals (NASDAQ:BCRX) +1.2%.
    • Other related tickers: Hemipherx BioPharma (NYSEMKT:HEB); Inovio Pharmaceuticals (NASDAQ:INO); NewLink Genetics (NASDAQ:NLNK).
  • Dec. 24, 2014, 7:11 AM
    • The FDA grants Orphan Drug status to BioCryst Pharmaceuticals' (NASDAQ:BCRX) BCX4161 for the prevention of acute attacks of angioedema in patients with hereditary angioedema (HAE).
    • BCX4161 is a novel selective inhibitor of plasma kallikrein which, in turn, suppresses bradykinin production. Bradykinin is the mediator of acute swelling attacks in patients with HAE.
    • Among the benefits of the Orphan Drug designation is a seven-year period of market exclusivity if approved.
    | 1 Comment
  • Dec. 22, 2014, 6:55 AM
    • The FDA approves BioCryst Pharmaceuticals' (NASDAQ:BCRX) Rapivab (peramir injection) for the treatment of adult (18 years and older) patients with acute uncomplicated influenza who have been symptomatic for no more than two days.
    • Rapivab is a neuraminidase inhibitor that is administered as a single 600 mg dose intravenously over 15 to 30 minutes.
    • Shares are up 12% premarket on light volume.
    | Comment!
  • Dec. 18, 2014, 12:56 PM
    | Comment!
  • Dec. 15, 2014, 8:02 AM
    • The first patient has been dosed in a Phase 1 study assessing the safety, tolerability and pharmacokinetics of BioCryst Pharmaceuticals' (NASDAQ:BCRX) BCX4430 for the treatment of hemorrhagic fever caused by viruses such as Ebola and Marburg. The trial will enroll up to 88 healthy volunteers who will receive a singe injection of BCX4430 in part one of the trial and will receive it over seven days in part two.
    • BCX4430 is an RNA dependent-RNA polymerase inhibitor that has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families.
    • The National Institute of Allergy and Infectious Diseases, National Institutes of Health and the Department of Health and Human Services are funding the work.
    | Comment!
  • Dec. 5, 2014, 1:57 PM
    • As expected, the Biotechnology Industry Organization (BIO) gives a resounding thumbs up in support of adding Ebola to the FDA Priority Review Voucher Program Act. Under the act, developers of a vaccine or treatment for a qualified tropical disease receive a voucher for FDA priority review for another product of its choice.
    • Late Wednesday, the U.S. House of Representatives voted unanimously to add Ebola to the Act. Additional refinements to the legislation include making it easier for the Secretary of Health and Human Services to add to the list of qualified diseases, allowing the vouchers to be sold and transferred multiple times and shortening the timeline for notifying the FDA of the intention to use a priority review voucher.
    • The changes bring the tropical diseases priority review voucher program more in line with the rare pediatric disease priority review voucher program.
    • Ebola-related tickers: (GSK +0.2%)(JNJ +0.5%)(MRK +1%)(NLNK +2.2%)(TKMR -1.4%)(HEB +0.6%)(SRPT -0.8%)(BCRX +0.8%)(CMRX +3.2%)
  • Dec. 5, 2014, 7:19 AM
    • Doctors say that simple intravenous fluid drips could save the lives of many Ebola patients, but they are not being deployed due to a perception that no treatment will work.  Many patients are succumbing to extreme dehydration and electrolyte depletion caused by vomiting and diarrhea, according to Ian Roberts of the London School of Hygiene and Tropical Medicine and Anders Perner of Copenhagen University. "Ebola treatment must be more that just a setting for quarantine. Patients will be reluctant to attend treatment centers unless the care they superior to the care provided by family members."
    • The epidemic in West Africa has claimed more than 6,000 lives out of ~17,000 that have been infected. All but 15 of the deaths have occurred in Sierra Leone, Guinea and Liberia.
    • ETFs: IRY, IXJ
  • Nov. 20, 2014, 11:03 AM
    • The Securities and Exchange Commission suspends trading in thinly-traded nano caps Bravo Enterprises (OTCQB:OGNG), Immunotech Labs (OTCPK:IMMB), Myriad Interactive Media (MYRY) and Wholehealth Products (OTCPK:GWPC) citing a lack of publicly available information about the firms' operations.
    • The SEC can suspend trading in a stock for 10 days and prohibit broker-dealers from soliciting buyers and sellers until certain reporting requirements are met.
    • Ebola Small Cap Index (based on trading behavior): (OTCQB:AEMD -7%)(HEB +1.4%)(TKMR +0.2%)(NLNK +5.4%)(NNVC +2.9%)(INO +5%)(OTCQB:GOVX -2.1%)(SRPT +3.5%)(CMRX -1.3%)(PLX -0.9%)(NSPH -1.4%)(BCRX +0.4%)(LAKE -1.9%)(APT -2.4%)(VSR)(SMED +0.7%)
  • Nov. 17, 2014, 12:06 PM
    • Nano cap Aethlon Medical (OTCQB:AEMD +29.8%) jumps on massive turnover of 10M shares in response to its report of the successful treatment of a critically-ill Ebola patient in Germany with its Hemopurifier bio-filtration device. In a post-treatment analysis, the device captured 242M Ebola viruses. The patient is expected to make a full recovery.
    • The Hemopurifier targets the broad-spectrum elimination of viruses and immunosuppressive proteins from the blood.
    • The stock has more than tripled since mid-October when the first treatment with the Hemopurifier was reported.
    • Some of the members of the trading behavior-characterized Ebola Small Cap Index have completed their round trips. (HEB +1.2%)(TKMR +5.1%)(NLNK +2.5%)(NNVC -3.8%)(INO -8.5%)(OTCQB:GOVX)(SRPT -0.7%)(CMRX +4.4%)(PLX -1%)(NSPH -0.2%)(BCRX +0.7%)(LAKE +1.3%)(APT +0.2%)(VSR -0.7%)(SMED -2.7%)
  • Nov. 6, 2014, 6:51 AM
    • BioCryst Pharmaceuticals (NASDAQ:BCRX): Q3 EPS of -$0.12 beats by $0.08.
    • Revenue of $3.24M (+35.6% Y/Y) beats by $1.13M.
    • Press Release
    | Comment!
  • Nov. 5, 2014, 5:30 PM
  • Nov. 2, 2014, 10:21 AM
    • BioCryst Pharmaceuticals (NASDAQ:BCRX) will report Q3 results the morning of November 6. The conference call will begin at 11:00 am ET.
    • Consensus view is a loss of ($0.20) per share on revenues of $2.1M.
    | Comment!
Visit Seeking Alpha's
BCRX vs. ETF Alternatives
Company Description
Biocryst Pharmaceuticals Inc is abiotechnology company. The Companydesigns, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.
Sector: Healthcare
Industry: Biotechnology
Country: United States